B
BridgeBio Pharma, Inc. (BBIO)
NMS – Real vaqt narxi. Valyuta: USD
65.95
+1.27 (1.96%)
Yopilishda: May 12, 2026, 4:00 PM EDT
66.01
+0.06 (0.09%)
Bozor oldidan: May 13, 2026, 6:27 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
65.95
+1.27 (1.96%)
Yopilishda: May 12, 2026, 4:00 PM EDT
66.01
+0.06 (0.09%)
Bozor oldidan: May 13, 2026, 6:27 AM EDT
BridgeBio Pharma, Inc., biopharmatsiyaviy kompaniya, genetik kasalliklarga chalingan bemorlar uchun dori-darmonlarni kashf qiladi, ishlab chiqadi va yetkazib beradi. Kompaniya Attruby, yovvoyi turdagi yoki transtiretin vositali amiloidoz (ATTR-CM) kardiyomiyopiyasini davolash uchun deyarli to'liq TTR stabilizatori bo'lgan keyingi avlod og'iz orqali yuboriladigan kichik molekulali preparatni taklif qiladi; NULIBRY brendi ostida molibden kofaktor etishmovchiligini davolash uchun sintetik tsiklik giranopterin monofosfatning tomir ichiga yuboriladigan preparati Fosdenopterin; va achondroplasia va hypochondroplasia bilan og'rigan bolalarni davolash uchun 3-bosqich klinik tadqiqotlarda bo'lgan FGFR1-3 selektiv tirozin kinaz inhibitori bo'lgan kam dozali infigratinib. Kompaniya, shuningdek, Autosomal Dominant Hypocalcemia Type 1 (ADH1) va Chronic Hypoparathyroidism (CHP) ni davolash uchun 3-bosqich klinik tadqiqotlarda bo'lgan kaltsiy sezuvchi retseptorining salbiy allosterik modulatori bo'lgan og'iz orqali yuboriladigan kichik molekulali Encaleretni ishlab chiqmoqda; LGMD2I ni davolash uchun 3-bosqich klinik tadqiqotlarda bo'lgan tadqiqot qilinayotgan, og'iz orqali yuboriladigan va kichik molekulali terapiya BBP-418; va Canavan kasalligi uchun tadqiqot qilinayotgan adenovirüs bilan bog'liq virus (AAV) gen terapiyasi BBP-812. Bundan tashqari, kompaniya mendelian, onkologiya va gen terapiyasi kasalliklari uchun mahsulotlarni ishlab chiqish bilan shug'ullanadi. Kompaniya Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University va Novartis International Pharmaceutical Ltd. bilan litsenziyalash va hamkorlik shartnomalariga ega. BridgeBio Pharma, Inc. 2015 yilda tashkil etilgan va shtab-kvartirasi Palo Alto, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Charles J. Homcy M.D. | Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director |
| Dr. Eric Michael David J.D., M.D., Ph.D. | Chief Executive Officer of Gene Therapy |
| Dr. Frank P. McCormick Ph.D. | Co-Founder, Chairman of Oncology & Director |
| Dr. Neil Kumar Ph.D. | Co-Founder, CEO & Director |
| Dr. Richard H. Scheller Ph.D. | Chairman of Research & Development |
| Dr. Thomas Trimarchi Ph.D. | CFO & President |
| Dr. Uma Sinha Ph.D. | Chief Scientific Officer |
| Mr. Eli M. Wallace Ph.D. | Chief Scientific Officer of Oncology |
| Mr. Matthew Outten CPC, MBA | Chief Commercial Officer |
| Ms. Maricel M. Apuli | Chief Accounting Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-08 | 8-K | ny20072667x2_8k.htm |
| 2026-05-07 | 8-K | bbio-20260506.htm |
| 2026-05-07 | 10-Q | bbio-20260331.htm |
| 2026-04-24 | DEFA14A | ny20065754x2_defa14a.htm |
| 2026-04-24 | ARS | ny20065754x3_ars.pdf |
| 2026-03-30 | 8-K | ef20069329_8k.htm |
| 2026-02-24 | 10-K | bbio-20251231.htm |
| 2026-02-12 | 8-K | ef20065539_8k.htm |
| 2026-01-21 | 8-K | ef20063486_8k.htm |
| 2026-01-12 | 8-K | ef20062706_8k.htm |